A Silent Outbreak of Hepatitis E Virus (HEV) Infection or False-Positive Reaction of Anti-HEV IgM after COVID-19 Vaccination? Epidemiological Investigation of an Outbreak in a Korean Factory Complex in 2022
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To investigate a reported outbreak of presumed hepatitis E virus (HEV) infection in a Korean food manufacturing facility and to explore the association between anti-HEV immunoglobulin M (IgM) positivity and coronavirus disease 2019 (COVID-19) infection or vaccination. Methods: Twenty-four cases of anti-HEV IgM positivity were reported among 646 workers at the facility in 2022. An epidemiological investigation was conducted, comprising HEV-RNA testing of blood and environmental samples, analysis of group meal records, and an association between anti-HEV IgM positivity and confirmed COVID-19 infection or vaccination. Results: All 24 patients were asymptomatic, with cases spread sporadically across the facility. HEV RNA was not detected in the serum or environmental samples. Four out of 340 meals (1.2%) showed a significantly higher proportion of anti-HEV positivity in each meal intake group than in the non-intake group on certain days. Although the cumulative rate of COVID-19 infection showed no difference, the anti-HEV IgM positive group showed significantly higher proportions of >2 doses of COVID-19 vaccination (83.3% vs 48.7%, p=0.021), vaccination within 90 days (45.8% vs 19.7%, p=0.008), and having the Moderna vaccine administered as the last vaccine (75.0% vs 14.5%, p<0.001) than those of the anti-HEV negative group. In four multivariable models, three or more COVID-19 vaccinations and the Moderna vaccine as the last vaccine were consistently associated with anti-HEV IgM positivity, while the specific day group meal intake was also a significant factor. Conclusions: This epidemiological investigation showed that anti-HEV IgM positivity may occur as a false-positive result related to COVID-vaccination over three times and use of the Moderna vaccine, although a portion of true HEV infection may not be excluded.
Abstract
Background/Aims: To investigate a reported outbreak of presumed hepatitis E virus (HEV) infection in a Korean food manufacturing facility and to explore the association between anti-HEV immunoglobulin M (IgM) positivity and coronavirus disease 2019 (COVID-19) infection or vaccination. Methods: Twenty-four cases of anti-HEV IgM positivity were reported among 646 workers at the facility in 2022. An epidemiological investigation was conducted, comprising HEV-RNA testing of blood and environmental samples, analysis of group meal records, and an association between anti-HEV IgM positivity and confirmed COVID-19 infection or vaccination. Results: All 24 patients were asymptomatic, with cases spread sporadically across the facility. HEV RNA was not detected in the serum or environmental samples. Four out of 340 meals (1.2%) showed a significantly higher proportion of anti-HEV positivity in each meal intake group than in the non-intake group on certain days. Although the cumulative rate of COVID-19 infection showed no difference, the anti-HEV IgM positive group showed significantly higher proportions of >2 doses of COVID-19 vaccination (83.3% vs 48.7%, p=0.021), vaccination within 90 days (45.8% vs 19.7%, p=0.008), and having the Moderna vaccine administered as the last vaccine (75.0% vs 14.5%, p<0.001) than those of the anti-HEV negative group. In four multivariable models, three or more COVID-19 vaccinations and the Moderna vaccine as the last vaccine were consistently associated with anti-HEV IgM positivity, while the specific day group meal intake was also a significant factor. Conclusions: This epidemiological investigation showed that anti-HEV IgM positivity may occur as a false-positive result related to COVID-vaccination over three times and use of the Moderna vaccine, although a portion of true HEV infection may not be excluded.
참고문헌 (18)
- Zeng DY, "Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019", J Hepatol, 75, pp.547~556 (2021)
- "Fact sheets" (2015)[URL]
- Kamar N, "Hepatitis E virus infection", Nat Rev Dis Primers, 3, pp.17086~ (2017)
- Nimgaonkar I, "Hepatitis E virus : advances and challenges", Nat Rev Gastroenterol Hepatol, 15, pp.96~110 (2018)
- Jang JH, "Coexistence of IgM antihepatitis A virus and IgM antihepatitis E virus in acute viral hepatitis : a prospective, multicentre study in Korea", J Viral Hepat, 18, pp.e408~e414 (2011)
- Fogeda M, "Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E", J Clin Virol, 45, pp.259~261 (2009)
- Llovet LP, "Higher seroprevalence of hepatitis E virus in autoimmune hepatitis : role of false-positive antibodies", Liver Int, 40, pp.558~564 (2020)
- Heo NY, "Hepatitis E virus : epidemiology, diagnosis, and management", Korean J Gastroenterol, 74, pp.130~136 (2019)
- Jeong SH, "Current status of hepatitis e virus infection in Korea", Gut Liver, 5, pp.427~431 (2011)
- Yoon Y, "Hepatitis E virus(HEV)seroprevalence in the general population of the Republic of Korea in 2007-2009 : a nationwide cross-sectional study", BMC Infect Dis, 14, pp.517~ (2014)
- Yun H, "Seroprevalence of hepatitis a and e viruses based on the third Korea national health and nutrition survey in Korea", Osong Public Health Res Perspect, 2, pp.46~50 (2011)
- Song JE, "Multicenter analysis of clinical features and prognosis of COVID-19 patients with hepatic impairment", Gut Liver, 15, pp.606~615 (2021)
- Baldelli L, "SARS-CoV-2 infection and liver disease : a review of pathogenesis and outcomes", Gut Liver, 17, pp.12~23 (2023)
- Tahtinen S, "IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines", Nat Immunol, 23, pp.532~542 (2022)
- Grannis SJ, "Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2B. 1. 617. 2(Delta)variant predominance : nine states, June-August 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1291~1293 (2021)
- "Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine?" (2021)[URL]
- Korentzelos D, "COVID-19 mRNA vaccines may cause false reactivity in some serologic laboratory tests, including rapid plasma reagin tests", Am J Clin Pathol, 158, pp.162~166 (2022)
- Park HK, "Seroprevalence of antihepatitis E virus(HEV)in a Korean population : comparison of two commercial anti-HEV assays", BMC Infect Dis, 12, pp.142~ (2012)